RTP Mobile Logo
Hematologic Oncology Update: Nursing Edition, Issue 1, 2010
Released November 2010

Featuring interviews with John P Leonard, MD, Rafael Fonseca, MD, Kena C Miller, MSN, FNP and Mollie Moran, MSN, CNP, AOCNP. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    More than 45 pharmaceutical agents with more than 55 distinct FDA-approved indications are currently available for the management of hematologic cancer. Although this extensive list of available treatment options is reassuring to patients and oncology healthcare professionals, it poses a challenge to clinicians who must maintain up-to-date knowledge of appropriate clinical management strategies and their efficacies and toxicities. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update for Nurses features one-on-one discussions with leading hematologic oncology investigators and nurse practitioners. By providing information on the latest research developments in the context of expert perspectives, this activity assists oncology nurses, clinical nurse specialists and nurse practitioners with the formulation of state-of-the-art clinical management strategies to facilitate optimal patient care.

    PURPOSE STATEMENT


    To present the most current research developments in hematologic oncology and to provide the perspectives of investigators and nurse practitioners on the diagnosis and treatment of hematologic cancer.

    EDUCATIONAL OBJECTIVES FOR THIS ISSUE OF HEMATOLOGIC ONCOLOGY UPDATE FOR NURSES

    • Explore new supportive and therapeutic strategies to enhance the care of patients with non-Hodgkin’s lymphoma and multiple myeloma.
    • Develop a plan of care to address side effects and quality of life for patients with hematologic cancer.

    ACCREDITATION STATEMENT

    Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

    CREDIT DESIGNATION STATEMENT

    This educational activity for 2.6 contact hours is provided by Research To Practice during the period of November 2010 through November 2011.

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYMs Moran had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr LeonardConsulting Agreements: Biogen Idec, Biotest Pharmaceuticals Corporation, Calistoga Pharmaceuticals Inc, Celgene Corporation, Cephalon Inc, CT International, Eisai Inc, EMD Serono Inc, Genentech BioOncology, GlaxoSmithKline, Gloucester Pharmaceuticals, Immunomedics Inc, Intellikine, Johnson & Johnson Pharmaceuticals, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis, Wyeth. Dr FonsecaConsulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Medtronic Inc, Otsuka Pharmaceutical Co Ltd; Paid Research: Celgene Corporation, Onyx Pharmaceuticals Inc. Ms MillerAdvisory Committee and Speakers Bureau: Celgene Corporation, Millennium Pharmaceuticals Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff, planners, managers and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Celgene Corporation and Genentech BioOncology/Biogen Idec.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: November 2010
    Expiration date: November 2011

Acknowledge and close

Hematologic Oncology Update: Nursing Edition, Issue 1, 2010
Released November 2010

Featuring interviews with John P Leonard, MD, Rafael Fonseca, MD, Kena C Miller, MSN, FNP and Mollie Moran, MSN, CNP, AOCNP. (Audio Content)